Quantum Biopharma (QNTM) Total Current Liabilities (2018 - 2026)

Quantum Biopharma has reported Total Current Liabilities for 9 years, with the latest figure at $16.3 million in Q1 2026.

• Quarterly Total Current Liabilities rose 58.02% year-over-year to $16.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.3 million (up 58.02% YoY) and the FY2025 annual result came in at $6.1 million, down 9.29% from the prior year.
• Total Current Liabilities advanced to $16.3 million in Q1 2026 per QNTM's latest filing, from $6.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $16.3 million in Q1 2026 and troughed at $3.7 million in Q3 2024.
• A 5-year average of $8.0 million and a median of $6.7 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities plunged 41.69% in 2023, then soared 162.64% in 2025.
• Over 5 years, Total Current Liabilities stood at $7.8 million in 2022, then tumbled by 41.69% to $4.6 million in 2023, then surged by 46.29% to $6.7 million in 2024, then dropped by 9.29% to $6.1 million in 2025, then surged by 169.81% to $16.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $16.3 million, $6.1 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.